THE ECONOMIC RATIONALE FOR THE SUPPLEMENTATION OF CHOLECALCIFEROL IN THE TREATMENT OF HYPERTENSIONJournal: Journal of the Grodno State Medical University (Vol.18, No. 5)
Publication Date: 2020-10-02
Authors : Yakubova L. V.;
Page : 538-544
Keywords : vitamin D; arterial hypertension; costs; cost-effectiveness; cholecalciferol; blood pressure;
The aim of the study was to calculate the costs of lowering blood pressure (BP) in complex antihypertensive therapy of arterial hypertension (AH) with and without cholecalciferol. Material and methods. A total of 154 patients with grade II AH were included into the study. They were divided into the AH(+)Х group - those who received combined antihypertensive therapy plus cholecalciferol 2000 IU / day and the comparison group - AH(-)Х. Office BP and total vitamin D levels were measured. The costs of drug therapy were calculated. Results. On repeated examination, the level of vitamin D in the blood increased and in the AH(+)Х group it became higher (p = 0.0000001) than in the AH (-)Х group. The cost of drug therapy per person in the AH(+)Х group was higher than in the AH(-)Х group ($ 106.8 and $ 91.5, respectively), but the cost of reducing 1 mm Hg systolic BP in the AH(+)Х group was $ 3.9 less than in the AH(-)Х group.Conclusion. The economic costs of reducing systolic BP, with more frequent achievement of its target values, were the lowest in the complex therapy with cholecalciferol, especially in combination with a diuretic.
Other Latest Articles
Last modified: 2020-11-20 17:03:18